MO - Altria Group, Inc.
51.69 +0.19 (0.37%)
After hours: 7:07PM EST
| Previous Close | 50.37 |
| Open | 50.65 |
| Bid | 51.50 x 800 |
| Ask | 51.69 x 2200 |
| Day's Range | 50.40 - 51.54 |
| 52 Week Range | 42.40 - 66.53 |
| Volume | 8,232,123 |
| Avg. Volume | 12,759,881 |
| Market Cap | 96.514B |
| Beta (3Y Monthly) | 0.23 |
| PE Ratio (TTM) | 13.99 |
| EPS (TTM) | 3.68 |
| Earnings Date | Apr 25, 2019 |
| Forward Dividend & Yield | 3.20 (6.53%) |
| Ex-Dividend Date | 2018-12-24 |
| 1y Target Est | 56.80 |
Yahoo Finance•8 hours agoJuul is going after top tech talent from Amazon and Google
Juul has been targeting engineers from companies like Amazon and Google to revamp its e-commerce business—but also, perhaps, to shift its corporate image.
- Barrons.com•3 hours ago
Forget Gambling and Liquor. This Sin Stock Pays Big Dividends
On a scale of things you’ll want to admit to your friends, buying this stock is two notches below swearing at puppies
- Reuters•9 hours ago
Juul annual sales projected to top $3 bln after profitable 2018 -Bloomberg
E-cigarette maker Juul Labs Inc's revenue is expected to triple this year to about $3.4 billion following a profitable 2018, Bloomberg reported on Friday. The vaping device maker revealed its first official ...
Bloomberg•14 hours agoJuul Expects Skyrocketing Sales of $3.4 Billion, Despite Flavored Vape Restrictions
Juul forecasts revenue of $3.4 billion for 2019, almost triple what it generated last year, according to a person who was briefed on the numbers. Juul posted fourth-quarter revenue of $424 million, a 2.5 percent decline from the previous quarter, said the person, who asked not to be identified because the information is private. Over the same periods, Juul’s adjusted loss was $70.4 million, compared with a $17 million profit in the prior quarter.
- GlobeNewswire•yesterday
Cronos Group Inc. Shareholders Approve C$2.4 Billion Strategic Investment from Altria Group, Inc.
Cronos Group Inc. (CRON) (CRON.TO) (“Cronos Group” or the “Company”) announced that at a Special Meeting held today, the Company’s shareholders overwhelmingly approved the previously announced strategic investment agreement with Altria Group, Inc. (MO) (“Altria”). Pursuant to the agreement, at closing, Altria will make an approximately C$2.4 billion equity investment in Cronos Group (the “Transaction”) on a private placement basis in exchange for common shares (the “Shares”) in the capital of the Company.
- Zacks•yesterday
What Investors Need to Know About Investing in Marijuana Stocks
Let's look at what investors need to know about the marijuana industry and how to invest in the future of pot.
- Benzinga•yesterday
Wells Fargo Expects Tobacco Stocks To 'React Favorably' To Price Increases
Tobacco giants Altria Group Inc (NYSE: MO ) and Philip Morris International Inc. (NYSE: PM ) are raising prices on all of their cigarette brands, and investors should take this as a positive, according ...
- InvestorPlace•yesterday
Don’t Stress Recent Weakness in Canopy Growth Stock
Shares of Canopy Growth (NYSE:CGC) went parabolic to start 2019, as the leading Canadian cannabis company benefited from a series of industry-wide and company-specific catalysts which further illuminated a pathway towards big profits at scale. Year-to-date, CGC stock is up roughly 75%.Source: Shutterstock But stocks don't go up in straight lines forever. Indeed, CGC stock has experienced some weakness as of late. There were some margin concerns in the company's recent earnings report. There was news that the CFO is leaving the company later this year. And, there was a rare downgrade from Wall Street.All together, CGC stock currently sits about 8% off its 2019 highs.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 Healthy Dividend Stocks to Buy for Extra Stability This recent weakness isn't anything to be too concerned about. CGC stock had come very far, very fast and had jumped into technically overbought territory. It was due for a natural pullback. Now, it's due for some natural consolidation in the $40 range.Importantly, though, CGC stock is not fundamentally overvalued. Recent developments and quarterly numbers underscore that Canopy is on track to potentially become a $100 billion company one day. As such, the long-term potential ($16 billion market cap today) is enormous, with mitigated enough risk to warrant sticking with CGC stock for the long haul.Ultimately, recent weakness is just a bump in the road and this road will eventually take CGC stock much higher. Canopy Stock Was Due for a PullbackOne of the truest statements in the entire investment world is that stocks don't go up in straight lines forever. That which goes very far, very fast, will ultimately pull back. That doesn't say anything about the nature of the stock or the company. It's simply the theory of financial gravity -- buyers won't out-buy sellers forever.Recent weakness in Canopy stock should be perceived through this lens. At one point in time, Canopy stock was up a whopping 90% year to date. That point in time was Jan. 28, meaning shares of Canopy had rallied 90% in less than a month. That is a textbook definition of a stock going very far, very fast.Granted, the big rally was rooted in fundamentals. Namely, Canopy flexed its muscles as the leader in the global cannabis market by expanding global distribution, pushing into the U.S. hemp market, and reporting record third-quarter numbers. Still, up 90% in less than a month, CGC stock was overbought. Regardless of the fundamentals, it needed to cool off.Now, it's cooling off. It will continue to cool off for the foreseeable future. Investor sentiment needs to calm down and become less euphoric. The moving averages need to catch up. Investors should expect CGC stock to be range bound between $40-$50 for a few weeks.Thereafter, CGC stock will resume its rally higher. Why? Because the fundamentals continue to point to huge upside in a long-term window. The Fundamentals Remain HealthyThe long-term bull thesis on CGC stock is simple.Canopy Growth is the head-and-shoulders leader in the now fully legal Canadian cannabis market and will use that leadership position and a $4 billion investment from and partnership with global alcoholic beverage giant Constellation Brands (NYSE:STZ) to become one of, if not the, biggest player in the global cannabis space. This space projects to be a several-hundred-billion-dollar industry within the next 10 to 15 years as fully legal becomes the global norm. As such, Canopy reasonably projects to do several billion dollars in revenues and profits within the next 10 to 15 years, and that will easily translate into a $100 billion-plus market cap for CGC stock using market average multiples.All appears to be intact with this long-term bull thesis at the current time.Recent quarterly numbers suggest that Canopy is still the dominant force in the Canadian cannabis market. Canopy reported over $60 million in net revenue in the third quarter. That is, far and away, the largest revenue quarter any Canadian cannabis company has reported. Ever. It's also up nearly 300% year over year. Canopy also sold over 10,000 kilograms of cannabis during the quarter -- far above what peers are reporting and up 350% year over year. Clearly, Canopy is still dominating the Canadian cannabis market.Meanwhile, Canopy is the first Canadian cannabis company to make a big push into the U.S. hemp market with operations set to proceed in New York. Canopy is also using its cash to acquire multiple smaller players, further increasing its reach and portfolio of cannabis brands. The company is also making big moves in Peru, Poland and the United Kingdom.Overall, everything is moving in the right direction for Canopy. The company is continuing to dominate fully legal cannabis markets, is making big moves into newly legal cannabis markets and is expanding its reach and portfolio through acquisitions. In other words, Canopy looks like it's in the early stages of becoming the Constellation Brands or Altria (NYSE:MO) of the cannabis industry.So long as that thesis remains true, fundamentals will keep CGC stock on a long-term uptrend. Bottom Line on CGC StockCanopy Growth is a long-term winner going through some near term consolidation. In the big picture, this near-term consolidation is healthy. * 10 Hot Stocks Leading the Market's Blitz Higher CGC stock will resume its uptrend later in 2019 as more fundamental catalysts arrive (strong quarters, further legalization, deeper global distribution, Wall Street upgrades, so on and so forth). Until then, buying on weakness and holding for the long haul remains the winning strategy.As of this writing, Luke Lango was long CGC. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 10 Best Cheap Stocks to Buy Right Now * 5 Stocks Under $5 to Buy Before They Soar * 5 Consumer Stocks to Cash Out Of Compare Brokers The post Donat Stress Recent Weakness in Canopy Growth Stock appeared first on InvestorPlace.
- Thomson Reuters StreetEvents•2 days ago
Edited Transcript of MO earnings conference call or presentation 31-Jan-19 2:00pm GMT
Q4 2018 Altria Group Inc Earnings Call
- MarketWatch•2 days ago
Altria's stock jumps toward 2-month high after Wells Fargo's bullish call post CAGNY
Share of Altria Group Inc. jumped 3.3% toward a 2-month high in afternoon trade Wednesday, and have recovered nearly everything they lost since announcing a $12.8 billion stake in e-vapor company Juul Labs Inc. Analyst Bonnie Herzog at Wells Fargo said she is "incrementally more confident" in Altria's strategy of maximizing returns on its core brands, including Marlboro, while pursuing new avenues of growth in e-vapor and cannabis, through its $1.8 billion investment in Cronos Group Inc. , following the company's presentation at the Consumer Analyst Group of New York (CAGNY) conference. She reiterated her outperform rating and $65 stock price target. The stock closed at $51.40 on Dec. 19, just before Altria announced is Juul investment, then fell to a more than 5-year low of $43.33 on Jan. 24. Since then, the stock has soared 17%. in comparison, the SPDR Consumer Staple Select Sector ETF has advanced 5.2% since Jan. 24 and the Dow Jones Industrial Average has gained 5.7%.
- Motley Fool•2 days ago
3 Arguments For and Against Buying Cronos Group
Pot stock Cronos Group has been a top performer in 2019, but opinions vary wildly on where it'll head next.
- Business Wire•2 days ago
Altria Presents at the Consumer Analyst Group of New York Conference; Reaffirms Full-Year 2019 Earnings Guidance
Altria Group, Inc. is participating in the Consumer Analyst Group of New York Conference in Boca Raton, Florida today. Howard Willard, Altria’s Chairman and Chief Executive Officer, and other members of Altria’s senior management team will highlight Altria’s recent strategic investments, the current regulatory environment and Altria’s plans for its wholly-owned tobacco businesses and diverse business ...
- Investing.com•3 days ago
Altria Rises 3%
Investing.com - Altria (NYSE:MO) rose by 3.03% to trade at $50.48 by 10:34 (15:34 GMT) on Wednesday on the NYSE exchange.
- CNBC Videos•2 days ago
Best bets in staples
Nik Modi of RBC Capital Markets breaks down his top picks in the consumer staple sectors.
